Statins in esophageal cancer cell lines: Promising lead?

American Journal of Gastroenterology

Volumn 103, Issue 4, 2008, Pages 838-841

  Hawk, Ernest T ^a   Viner, Jaye L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RAS PROTEIN;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; DRUG MECHANISM; ENZYME INACTIVATION; ESOPHAGUS CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BARRETT ESOPHAGUS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; PRAVASTATIN; SIMVASTATIN;

EID: 41849147509     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01768.x     Document Type: Review

References (42)

1. Lagergren J. Etiology and risk factors for oesophageal adenocarcinoma: Possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol 2006 20 : 803 12.
2. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000 29 : 645 54.
3. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 340 : 825 31.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70.
5. Atherfold PA, Jankowski JA. Molecular biology of Barrett's cancer. Best Pract Res Clin Gastroenterol 2006 20 : 813 27.
6. Buttar NS, Wang KK. Mechanisms of disease: Carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 2004 1 : 106 12.
7. Feagins LA, Souza RF. Molecular targets for treatment of Barrett's esophagus. Dis Esophagus 2005 18 : 75 86.
8. Koppert LB, Wijnhoven BP, van Dekken H, et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005 92 : 169 90.
9. Peters CJ, Fitzgerald RC. Systematic review: The application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment Pharmacol Ther 2007 25 : 1253 69.
10. Ogunwabi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barvett's esophageal adenocarcinoma cells. AM J Gastroenterol 2008 103 : 825 37.
11. Graaf MR, Richel DJ, van Noorden CJ, et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004 30 : 609 41.
12. Collisson EA, Kleer C, Wu M, et al. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003 2 : 941 8.
13. Kikuchi T, Nagata Y, Abe T. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J Neurooncol 1997 34 : 233 9.
14. Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 1991 3 : 141 7.
15. Shibata MA, Kavanaugh C, Shibata E, et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003 24 : 453 9.
16. Suzuki S, Tajima T, Sassa S, et al. Preventive effect of fluvastatin on ulcerative colitis-associated carcinogenesis in mice. Anticancer Res 2006 26 : 4223 8.
17. Narisawa T, Fukaura Y, Tanida N, et al. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine- induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996 180 : 131 8.
18. Narisawa T, Fukaura Y, Terada K, et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994 15 : 2045 8.
19. Narisawa T, Morotomi M, Fukaura Y, et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996 87 : 798 804.
20. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005 352 : 2184 92.
21. Vinogradova Y, Hippisley-Cox J, Coupland C, et al. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: Nested case-control study. Gastroenterology 2007 133 : 393 402.
22. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007 99 : 32 40.
23. Jacobs EJ, Rodriguez C, Brady KA, et al. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006 98 : 69 72.
24. Khurana V, Bejjanki HR, Caldito G, et al. Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans. Chest 2007 131 : 1282 8.
25. Khurana V, Sheth A, Caldito G, et al. Statins reduce the risk of pancreatic cancer in humans: A case-control study of half a million veterans. Pancreas 2007 34 : 260 5.
26. Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006 26 : 298 303.
27. Graaf MR, Beiderbeck AB, Egberts AC, et al. The risk of cancer in users of statins. J Clin Oncol 2004 22 : 2388 94.
28. Bonovas S, Filioussi K, Tsavaris N, et al. Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006 24 : 4808 17.
29. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: A meta-analysis. JAMA 2006 295 : 74 80.
30. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997 278 : 313 21.
31. Shiga C, Shiga K, Sasano H, et al. A point mutation of c-Ki-ras gene was found in human esophageal carcinoma cell lines but not in primary esophageal carcinomas. Biochem Biophys Res Commun 1992 187 : 515 21.
32. Arber N, Shapira I, Ratan J, et al. Activation of cK-ras mutations in human gastrointestinal tumors. Gastroenterology 2000 118 : 1045 50.
33. Galiana C, Lozano JC, Bancel B, et al. High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. Mol Carcinog 1995 14 : 286 93.
34. Jankowski J, Coghill G, Hopwood D, et al. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 1992 33 : 1033 8.
35. Lord RV, O'Grady R, Sheehan C, et al. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol 2000 15 : 730 6.
36. Trautmann B, Wittekind C, Strobel D, et al. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus. Eur J Gastroenterol Hepatol 1996 8 : 799 804.
37. Jaiswal K, Lopez-Guzman C, Souza RF, et al. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006 290 : G335 42.
38. Souza RF, Shewmake K, Pearson S, et al. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2004 287 : G743 8.
39. Beales IL, Ogunwobi O, Cameron E, et al. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: A histopathological and functional study. BMC Cancer 2007 7 : 97.
40. Sagatys E, Garrett CR, Boulware D, et al. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Hum Pathol 2007 38 : 1526 31.
41. Harris JC, Clarke PA, Awan A, et al. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004 64 : 1915 9.
42. Jaiswal K, Tello V, Lopez-Guzman C, et al. Bile salt exposure causes phosphatidyl-inositol-3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line. Surgery 2004 136 : 160 8.